Wearable Cardioverter Defibrillators Market Overview
Wearable Cardioverter Defibrillators Market is estimated to reach at a CAGR of 25.45% during the forecast period (2024-2031). The rechargeable external device wearable cardioverter defibrillator (WCD) can be worn under the clothing all day long and protects the user from potentially life-threatening ventricular tachyarrhythmias.
Market Scope and Summary
| Metrics | Details |
| Market CAGR | 25.45% |
| Segments Covered | By Conditions, By Implant Type, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To know more Insights Download Sample
Market Dynamics
The increase in the prevalence of cardiovascular disease and increasing technological development is assumed to drive the wearable cardioverter-defibrillators in the forecast period.
The increase in the prevalence of cardiovascular disease is expected to drive the wearable cardioverter defibrillators market
The estimated study of Global Burden of Disease of age-standardized death rate of cardiovascular disease272 per 100,000 population in India is higher than the global average population. According to the Journal of the American College of Cardiology, the number of people dying from cardiovascular disease is rising steadily, globally including one-third of all deaths in 2019, that reviewed the total magnitude of CVD burden and trends over 30 years around the world. Implantable cardioverter defibrillators (ICDs) efficacy has been demonstrated by multiple clinical trials to prevent sudden cardiac death (SCD) among specific high-risk populations. Because of the increasing use of the wearable cardioverter defibrillators and uncertainty of indications among practicing cardiovascular health professionals, this science advisory was prepared by the American Heart Association.
The wearable cardioverter-defibrillator is an alternative antiarrhythmic device that provides continuous cardiac monitoring and defibrillation capabilities through a non-invasive, electrode-based system. The WCD is highly effective at restoring sinus rhythm in patients with ventricular tachyarrhythmia. Using the WCD one randomized trial in patients with recent myocardial infarction at increased risk for arrhythmic death reported a decrease in mortality overall despite no sudden cardiac death mortality benefit. The current clinical indications for WCD use vary and continue to evolve as experience with this technology increases.
The increasing technological development is assumed to drive the wearable cardioverter-defibrillators in the forecast period
The implantable cardioverter-defibrillator (ICD) is central in the prevention of sudden cardiac death (SCD). Current guidelines recommend ICD implantation for secondary and primary prevention in patients with an established high risk of SCD. Currently, only one WCD system (LifeVest®, ZOLL, Pittsburgh, PA, USA) is available. The WCD is a system that consists of a harness-style vest that contains non-adhesive dry tantalum oxide capacitive sensing electrodes and self-gelling defibrillator electrodes. This lightweight vest (0.8 kg) is designed to be worn continuously under normal clothing and is available in different sizes. A monitor is worn around the waist (or shoulder harness) and contains sensing circuits, batteries, and capacitors. The device has a system of audible and vibratory alerts to warn a patient of an imminent shock. The patient can abort the shock by pressing buttons on the monitor.
Technological advances are considerable in cardiac pacing and defibrillation, from the latest venous accesses for implantation to recent locations for permanent pacing or non-endovenous ICD. The imagination of researchers and device companies seems to be limitless.
The lack of awareness and use of wearable cardioverter defibrillators is expected to hamper the market
Wearable cardioverter-defibrillators (WCD, LifeVest, ZOLL) can protect from sudden cardiac death, bridging a vulnerable period until a decision on implantable cardioverter-defibrillator (ICD) implantation can be reached. WCD is commonly used for three months or less. It is unknown which patients use WCD longer and which patients are most likely to benefit from it. Hypothesis. Extended use of WCD is reasonable in selected cases based on underlying heart disease and overall patient risk profile. Wearable devices can impact directly clinical decision-making. Some users think that wearable technologies improve the quality of patient care by reducing the cost. The big data generated by wearable devices is both a opportunity and challenge for researchers who can apply more artificial intelligence (AI) techniques to these in the future data. Most technologies are still in their prototype stages. Issues such as security ,user acceptance, big data and ethics concerns in this technology l need to be addressed still to enhance the functions and usability of these devices for practical use.
A wearable cardioverter defibrillator is an option for temporary therapy that can protect patients vulnerable to cardiac arrhythmias by preventing, aborting sudden cardiac death, and lowering mortality rates. Although there are barriers to overcome, promoting consistent identification and increasing awareness may increase the use of this life-saving therapy of these at high-risk, decrease the current gap in care, and improve clinical decision-making.
COVID-19 Impact on Market
The healthcare industry has been affected by COVID-19. To curb its growth, the government imposed a lockdown. People are fearful they will experience occupational effects and negative health from the COVID-19 pandemic. This has positively affected the wearable cardioverter defibrillators market as people can stay at home and get treated without visiting the doctor in person.
Market Segment Analysis
The Peripartum Cardiomyopathy segment is expected to dominate the wearable cardioverter defibrillators market
Peripartum cardiomyopathy is a heart muscle weakness that begins sometime during the final month of pregnancy through about five months after delivery, without any other known cause. It is now considered cardiomyopathy of an unknown cause that occurs in the peripartum period in women without pre-existing heart disease. Peripartum cardiomyopathy is relatively rare but devastating, with reported mortality rates between 18% and 56%.
Patients with peripartum cardiomyopathy (PPCM) have sudden cardiac death rates (SCD) of 7-56%; half of these occur <12 weeks of delivery. Ventricular recovery occurs in 30 -50% of PPCM, often within six months. Implantable cardioverter-defibrillator (ICD) therapy is used for persistent ventricular dysfunction. SCD risk before ICD implant is unknown. Risk factors for PPCM include non-Caucasian race, gestational hypertension, twin pregnancy, multiparity, and older age. The WCD is composed of four dry, no adhesive electrodes for monitoring, incorporated into a chest strap assembly three defibrillation electrodes and a defibrillation unit carried on a waist belt. The monitoring electrodes are circumferentially positioned around the chest, held by tension from an elastic belt and provides two surface electrocardiogram (ECG) leads. In a vest assembly the defibrillation electrodes are positioned for apex-posterior defibrillation. Proper fitting is required to achieve adequate skin contact to avoid noise and frequent alarms. PPCM patients with severely reduced LVEF have an elevated risk for ventricular tachyarrhythmias early after diagnosis. Therefore, the use of the WCD should be considered in all women with early-stage PPCM and severely reduced LVEF during the first six months after initiation of heart failure therapy.
Implantable Cardioverter Defibrillator (ICD) dominated the wearable cardioverter defibrillators market
A battery-powered device, implantable cardioverter defibrillator that keeps track of the heart rate is placed under the skin. Thin wires connect the ICD to the heart. The device will deliver an electric shock if an abnormal heart rhythm is detected, to restore a normal heartbeat if the heart beats chaotically and too fast. They have been very useful in preventing sudden death in patients with sustained, known ventricular tachycardia or fibrillation. Studies have shown that they may prevent cardiac arrest in high-risk patients who haven't had it but are at life-threatening risk for ventricular arrhythmias. It is implanted under the skin, just under the collarbone. It detects arrhythmias and responds with electrical signals to restore your heart's normal rhythm.
They detect and stop arrhythmias. The device continuously monitors heartbeat and delivers electrical pulses to restore when necessary the heart rhythm to normal. It differs from a pacemaker another implantable device used to help control abnormal heart rhythms. It is placed surgically under skin, usually below the left collarbone. One or more flexible, insulated wires run from the ICD through veins to heart. Because the ICD monitors constantly for abnormal heart rhythms and instantly tries to correct them, it helps when the heart stops beating even when the patient is far from the nearest hospital. It has become standard treatment cardiac arrest, and are increasingly being used for high risk of sudden cardiac arrest. Sudden death from cardiac arrest can be lowered by ICD risk than medication alone.
The home care settings are assumed to dominate the market
As people mostly prefer home treatment and are spending much on resources to get better treatment at home. Since COVID-19 has made it difficult for patients to visit hospitals, it is easy for physicians to assist patients virtually due to advancements in technology. ZOLL LifeVest is used to detect a life-threatening rapid heart rhythm and automatically deliver a treatment shock to restore a normal rhythm. From detecting a rapid life-threatening heartbeat to automatically delivering a shock, the entire event takes usually less than a minute.
Wearable cardioverter defibrillators does not require the assistance of an emergency personnel or professional for it to work. It can protects patient even when they are alone. With a WCD, patients can continue to do many of the things like spending time without worrying with friends and family, about the risk of SCD. A patient should only remove their ZOLL LifeVest WCD while taking bath or a short shower. If possible, this should be done only when someone is home with the patient,.
Market Geographical Share
North America region is expected to dominate the wearable cardioverter defibrillators market
Due to the growing incidence of diseases, and healthcare system in this region is assumed to dominate the wearable cardioverter defibrillators market.
In the U.S, every 36 seconds a person dies from cardiovascular disease. About 655,000 Americans die from heart disease each year that's 1 in every four deaths. According to a report, nearly half of all U.S. adults have some type of cardiovascular disease, a percentage that reflects recently updated guidelines for treating high blood pressure. High blood pressure also known as hypertension – can lead to heart attack, heart failure and stroke.
On average than any other nation, the United States spends more on health care services than twice as much per person as the other countries. These expenditures are financed by a mixture of complex individual payments, public payers and private insurance There is no single system of health insurance nationwide. The U.S. healthcare system is characterized as the world's most expensive yet least effective compared with other nations. Major healthcare costs drivers are institutionalized medical practices ,technology-induced costs and consumer behavior reimbursement policies. Hence, the increasing incidence of heart diseases and advanced healthcare structures will increase the demand for wearable cardioverter-defibrillators.
Market Competitive Landscape
Major key players in the wearable cardioverter defibrillators market are ZOLL Medical Corporation, Medtronic, St. Jude Medical LLC, Boston Scientific Corporation, LivaNova, Koninklijke Philips N.V., Cardiac Science, Physio-Control Inc., Nihon Kohden Corporation Defibtech LLC, Tianjin JingMing New Tech. Devp. Co., Ltd, HANSON MEDITEC CO., LTD and Huaian Meide Medical Instrument Co., Ltd
Wearable Cardioverter Defibrillators Market Key Companies to Watch
Cardiac Science Corporation
Overview: Cardiac Science Corporation develops, manufactures, and markets diagnostic and therapeutic cardiology products. The Company offers automated external defibrillators, diagnostic workstations, and systems. Cardiac Science serves patients worldwide.
Product Portfolio: Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems.
Key Development: ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, confirmed that it has completed the previously announced acquisition of Cardiac Science® Corporation, a leading provider of automated external defibrillators (AEDs), related services, and accessories.
The wearable cardioverter defibrillators market report would provide an access to an approx. 60 market data table, 50 figures and 180 pages.
